Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Metformin 500 mg Prolonged Release Tablets
NCT05124730Phase 1Completed
- Sponsor
- Farmak
- Start
- May 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Farmak. Primary endpoints: Area under the concentration-time curve from time zero to the last measurable concentration up to 36 hours and Maximum plasma concentration up to 36 hours. Started May 2021; status: completed.
02
Drugs
metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05124730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05124730.